SCHEDULE 13G: BlackRock Discloses 5.5% Stake in Soleno Therapeutics

BlackRock, Inc. has reported a significant passive ownership stake of 5.5% in Soleno Therapeutics Inc., holding over 2.7 million shares of common stock.

Summary

• BlackRock, Inc. has filed a Schedule 13G, disclosing its beneficial ownership in Soleno Therapeutics Inc.
• BlackRock, Inc. beneficially owns an aggregate of 2,766,225 shares of Soleno Therapeutics Inc. common stock.
• This ownership represents 5.5% of the total outstanding common stock of Soleno Therapeutics Inc.
• BlackRock holds sole voting power over 2,702,841 shares and sole dispositive power over 2,766,225 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The filing was made pursuant to Rule 13d-1(b), which applies to institutional investors who do not intend to acquire or influence control of the issuer.
• Several BlackRock subsidiaries are identified as beneficially owning shares, with BlackRock Investment Management, LLC specifically noted as owning 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a major institutional investor has disclosed a significant stake, which can be interpreted as a vote of confidence in the issuer. However, it is a factual disclosure without explicit forward-looking statements or performance metrics.

Positives

• BlackRock's acquisition of a 5.5% stake signals significant institutional confidence in Soleno Therapeutics Inc.
• The passive nature of the investment, as indicated by the Schedule 13G filing, suggests a long-term holding strategy by a major asset manager.

Future Outlook

NA

Industry Context

Schedule 13G filings are standard disclosures by institutional investors like BlackRock when they acquire more than 5% of a company's voting stock, indicating a passive investment rather than an intent to control or influence the company. This type of filing is common for large asset managers who hold diversified portfolios.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like BlackRock can be viewed positively, potentially increasing investor confidence and attracting further investment.

Key Dates

Keywords

BlackRock, Soleno Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Passive Investment